Glaukos
GKOS
Market cap $5.04B

88.30 USD

-1.96

2.17%

At close Apr 21, 4:00 PM EDT

After hours

88.30

+0.00

0.00%

1 day

-2.17%

5 days

-4.08%

1 month

-13.65%

3 months

-44.58%

6 months

-33.33%

Year to date

-41.01%

1 year

-10.76%

5 years

173.04%

10 years

182.83%

About: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Employees: 995

Healthcare Medical Devices

0

Funds holding %

of 7,419 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 40

21% more capital invested

Capital invested by funds: $7.08B [Q3] → $8.57B (+$1.49B) [Q4]

5.52% more ownership

Funds ownership: 107.89% [Q3] → 113.41% (+5.52%) [Q4]

2% more funds holding

Funds holding: 312 [Q3] → 318 (+6) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 105

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

29% less call options, than puts

Call options by funds: $46.1M | Put options by funds: $64.7M

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$140

59%

upside

Avg. target

$163

85%

upside

High target

$176

99%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target	98%upside $175	Outperform Maintained	16 Apr 2025
Piper Sandler Matt O'Brien 32% 1-year accuracy 16 / 50 met price target	87%upside $165	Overweight Maintained	15 Apr 2025
Truist Securities Richard Newitter 46% 1-year accuracy 22 / 48 met price target	59%upside $140	Buy Maintained	11 Apr 2025
Wells Fargo Larry Biegelsen 24% 1-year accuracy 11 / 46 met price target	81%upside $160	Overweight Maintained	21 Feb 2025
Needham David Saxon 28% 1-year accuracy 18 / 65 met price target	99%upside $176	Buy Maintained	21 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about GKOS published over the past 30 days

Glaukos Announces the Release of its 2024 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2024 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company's website here. “I am prou.

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to th.

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Zacks Investment Research

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space

Zacks Investment Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Here's Why You Should Retain Glaukos Stock in Your Portfolio

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Topcon Healthcare, Inc., RadiusXR, and Glaukos Corporation (NYSE: GKOS) announced a new collaboration and the launch of RadiusXR's new wearable vision testing platform - Inspire®. This collaboration unites RadiusXR's innovative visual field platform and Topcon Healthcare's global leadership in robotic diagnostics and digital healthcare solutions with Glaukos' commitment to expanding patient access by democratizing the diagnosis of ophthalmic diseases such a.

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Zacks Investment Research

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma and corneal health solutions.

GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment.

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

On Thursday, Glaukos Corp GKOS reported fourth-quarter sales of $105.5 million, up 28% year over year and beating the consensus of $100.49 million.

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Zacks Investment Research

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

See News Rankings

Charts implemented using Lightweight Charts™